
COYA Stock Forecast & Price Target
COYA Analyst Ratings
Bulls say
Coya Therapeutics is a clinical-stage biotechnology company with a promising pipeline of proprietary therapies focused on enhancing the function of regulatory T cells for the treatment of various diseases. With positive clinical data and partnerships in place, their venture into neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases has the potential to result in successful commercialization and revenue growth. While the company faces competition and regulatory challenges, their biomarker strategy and orphan drug designations provide some protection. As a development-stage company, valuation is complex and subject to forward assumptions.
Bears say
Coya Therapeutics is a clinical-stage biotechnology company with a negative outlook due to various reasons. First, the company has high operating expenses ($7.3 million in the second quarter of 2026) and limited revenue since it is still in the developmental stage. Additionally, the company is facing significant competition in the intensely competitive biotechnology and pharmaceutical industries. Furthermore, the company may need to raise additional capital in the future, which could dilute stockholders and be difficult to secure in the current financial environment.
This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares